新型冠状病毒肺炎疫情时期脑卒中绿色通道管理专家共识

2020-03-30 国家卫生计生委脑卒中防治工程委员会 首都医科大学学报.2020,41(2):1-5.

新型冠状病毒肺炎( COVID-19,以下简称新冠肺炎) 疫情已经扩展至全球,防控形势严峻。脑卒中是一种高发病率、高致残率、高病死率的疾病,急性缺血性脑卒中时间窗内的静脉溶栓治疗及大动脉闭塞的介入治疗

中文标题:

新型冠状病毒肺炎疫情时期脑卒中绿色通道管理专家共识

发布日期:

2020-03-30

简要介绍:

新型冠状病毒肺炎( COVID-19,以下简称新冠肺炎) 疫情已经扩展至全球,防控形势严峻。脑卒中是一种高发病率、高致残率、高病死率的疾病,急性缺血性脑卒中时间窗内的静脉溶栓治疗及大动脉闭塞的介入治疗是救治的关键措施,可以显著降低患者的致残率和病死率。脑卒中诊疗绿色通道的建立可以有效缩短救治时间,为患者争取良好的预后。在新冠肺炎疫情期间,如何同时兼顾脑卒中诊疗绿色通道救治工作和医务工作者、患者的防护工作,是当前的重点和难点。现制定新冠肺炎疫情防控下的脑卒中诊疗绿色通道管理专家共识,供各卒中中心参考。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=)] GetToolGuiderByIdResponse(projectId=1, id=0e3531c00188987a, title=新型冠状病毒肺炎疫情时期脑卒中绿色通道管理专家共识, enTitle=, guiderFrom=首都医科大学学报.2020,41(2):1-5., authorId=0, author=, summary=新型冠状病毒肺炎( COVID-19,以下简称新冠肺炎) 疫情已经扩展至全球,防控形势严峻。脑卒中是一种高发病率、高致残率、高病死率的疾病,急性缺血性脑卒中时间窗内的静脉溶栓治疗及大动脉闭塞的介入治疗, cover=https://img.medsci.cn/2020413/1586770781585_2020535.jpg, journalId=0, articlesId=null, associationId=1217, associationName=国家卫生计生委脑卒中防治工程委员会, associationIntro=国家卫生计生委脑卒中防治工程委员会 , copyright=0, guiderPublishedTime=Mon Mar 30 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>新型冠状病毒肺炎( COVID-19,以下简称新冠肺炎) 疫情已经扩展至全球,防控形势严峻。脑卒中是一种高发病率、高致残率、高病死率的疾病,急性缺血性脑卒中时间窗内的静脉溶栓治疗及大动脉闭塞的介入治疗是救治的关键措施,可以显著降低患者的致残率和病死率。脑卒中诊疗绿色通道的建立可以有效缩短救治时间,为患者争取良好的预后。在新冠肺炎疫情期间,如何同时兼顾脑卒中诊疗绿色通道救治工作和医务工作者、患者的防护工作,是当前的重点和难点。现制定新冠肺炎疫情防控下的脑卒中诊疗绿色通道管理专家共识,供各卒中中心参考。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=64, tagName=脑卒中), TagDto(tagId=98994, tagName=新型冠状病毒肺炎)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=64, guiderKeyword=脑卒中, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3624, appHits=69, showAppHits=3, pcHits=755, showPcHits=3613, likes=1, shares=7, comments=2, approvalStatus=1, publishedTime=Mon Apr 13 19:19:40 CST 2020, publishedTimeString=2020-03-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Apr 13 17:39:48 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 00:46:33 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=)])
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1228132, encodeId=2156122813290, content=有很好的临床指导作用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2fc5249377, createdName=147da216m47(暂无昵称), createdTime=Thu Jun 23 06:42:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014783, encodeId=93041014e833f, content=对临床有非常好的指导作用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97514728799, createdName=133429d297m, createdTime=Sun Sep 05 14:30:39 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
    2022-06-23 147da216m47(暂无昵称)

    有很好的临床指导作用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1228132, encodeId=2156122813290, content=有很好的临床指导作用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2fc5249377, createdName=147da216m47(暂无昵称), createdTime=Thu Jun 23 06:42:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014783, encodeId=93041014e833f, content=对临床有非常好的指导作用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=97514728799, createdName=133429d297m, createdTime=Sun Sep 05 14:30:39 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
    2021-09-05 133429d297m

    对临床有非常好的指导作用

    0